20_MSG_Annual-Meeting-Booklet_0917
Accepted Abstracts are posted on the RRNMF Journal at https://journals.ku.edu/rrnmf
Muscle and Nerve Journal, Volume 60, Supplement 2 is now live via Wiley Online Library.
Photos from the annual meeting are now available!
Presentation from Dr. William Meurer, Young Investigators Workshop
Date/Time
Date(s) – 09/20/2019 – 09/22/2019
Platinum: $50K+
Gold: $30K +
Silver: $15K +
Bronze: $5K +
• Name recognition in meeting agenda booklet
• Logo recognition on Annual Meeting Website
• Six-foot skirted display table available for duration of annual meeting
• Full complimentary registrations for 1 representatives, including all means and the opportunity to attend the sessions of your choice
Basic Corporate: $2K
• Name recognition in meeting agenda booklet
• Name recognition on Annual Meeting Website
• Six-foot skirted display table available for duration of annual meeting
$700 for each additional Pharma Representative to attend
If you qualify for expense reimbursement the deadline to submit is October 31, 2018. Please contact Liz Paulk at epaulk@kumc.edu.
The abstracts in the Muscle and Nerve can be found
https://onlinelibrary.wiley.com/toc/10974598/2018/58/S1
The incidence of type II glycogen-storage disease (Pompe disease) varies depending on ethnicity and geographic region. As of 2010, nine studies have been published documenting the incidence of Pompe disease. It is most common within the African American population, with an incidence of 1 in 14,000. In the U.S. more broadly speaking, the combined incidence of all three variants of the disease is 1 in 40,000. These estimates relied on the frequencies of three mutations in the gene acid alpha-glucosidase (GAA), leading to variants of the disease. Criteria for inclusion in the studies were often non-selective; in many cases, molecular genetic screening was done at birth. With such a high prevalence of Pompe disease reported, it is expected that large university medical centers specializing in neuromuscular diseases would see a higher incidence of Pompe disease among their patients. From a comparable Italian multicenter study, it appears that Pompe disease accounts for 3% of all patients presenting with proximal weakness with or without CK elevation.
was held September 23-25, 2017, at the Snowbird Ski and Summer Resort in Snowbird, Utah.
Link to the abstracts below:
https://onlinelibrary.wiley.com/doi/10.1002/mus.25768
The 2016 Muscle Study Group annual Meeting was held September 24-26, 2016, at the Snowbird Ski & Summer Resort in Snowbird, UT. Please click on the following links to be directed to the presentation slides, Poster Abstracts, and agenda for the meeting.
Final Agenda
Abstracts: Link to Abstracts
Presentations: Link to Presentations
Sponsors
Spinal Muscular Atrophy (SMA) is the leading genetic cause of death in infancy. It is a devastating disease that leads to progressive loss of those nerve cells that control our muscle bulk and movement. Patients develop increasing weakness in all muscles, eventually including those needed for breathing. In more than half of patients, SMA starts in infancy and typically leads to death within the first 2 years of life. In others, the disease begins in childhood and leads to significant disability.
SMA is caused by a defect in the “Survival of Motor Neurons” (SMN1) gene. Researchers are hopeful to find a cure, because nature has provided humans with a second gene, almost an identical copy of the SMN1 gene. Normally, the second gene does not contribute much, but researchers think that its function can be increased by medications.
To find out whether these medications help patients with SMA, we have to conduct clinical trials. Here, we propose to prepare for clinical trials. We will invite SMApatients to join our research effort. We will examine them regularly to better understand their disease. The visits will include questions, physical exam, blood drawing, and sometimes X-rays and a skin biopsy. We will use modern computer methods to process the information. While we are doing this, we will plan a clinical trial. Once the clinical trial begins, we will offer SMA patients participation if they meet the criteria for that trial.
We will make sure that the participants’ privacy is maintained and that the study risks are as low as possible.
Identifying an effective SMA treatment is very important because there is currently none. Clinical trials are the only way to decide whether a new treatment works in SMA patients or not.
Sponsor: Columbia University
This study will look at the impact of ascorbic acid (Vitamin C) on the progression of disease in people with CMT1A as compared to volunteers receiving a placebo. This study will assess whether is it futile to proceed with a larger, longer-term, placebo-controlled study.
Sponsor: Wayne State University